Anti-Virulence Therapeutic Approaches for <i>Neisseria gonorrhoeae</i>

While antimicrobial resistance (AMR) is seen in both <i>Neisseria gonorrhoeae</i> and <i>Neisseria meningitidis</i>, the former has become resistant to commonly available over-the-counter antibiotic treatments. It is imperative then to develop new therapies that combat curren...

Full description

Saved in:
Bibliographic Details
Main Authors: Katherine Y. L. Lim (Author), Christopher A. Mullally (Author), Ethan C. Haese (Author), Emily A. Kibble (Author), Nicolie R. McCluskey (Author), Edward C. Mikucki (Author), Van C. Thai (Author), Keith A. Stubbs (Author), Mitali Sarkar-Tyson (Author), Charlene M. Kahler (Author)
Format: Book
Published: MDPI AG, 2021-01-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_8d814fc4c35e4fbca3dd5a66dee08080
042 |a dc 
100 1 0 |a Katherine Y. L. Lim  |e author 
700 1 0 |a Christopher A. Mullally  |e author 
700 1 0 |a Ethan C. Haese  |e author 
700 1 0 |a Emily A. Kibble  |e author 
700 1 0 |a Nicolie R. McCluskey  |e author 
700 1 0 |a Edward C. Mikucki  |e author 
700 1 0 |a Van C. Thai  |e author 
700 1 0 |a Keith A. Stubbs  |e author 
700 1 0 |a Mitali Sarkar-Tyson  |e author 
700 1 0 |a Charlene M. Kahler  |e author 
245 0 0 |a Anti-Virulence Therapeutic Approaches for <i>Neisseria gonorrhoeae</i> 
260 |b MDPI AG,   |c 2021-01-01T00:00:00Z. 
500 |a 10.3390/antibiotics10020103 
500 |a 2079-6382 
520 |a While antimicrobial resistance (AMR) is seen in both <i>Neisseria gonorrhoeae</i> and <i>Neisseria meningitidis</i>, the former has become resistant to commonly available over-the-counter antibiotic treatments. It is imperative then to develop new therapies that combat current AMR isolates whilst also circumventing the pathways leading to the development of AMR. This review highlights the growing research interest in developing anti-virulence therapies (AVTs) which are directed towards inhibiting virulence factors to prevent infection. By targeting virulence factors that are not essential for gonococcal survival, it is hypothesized that this will impart a smaller selective pressure for the emergence of resistance in the pathogen and in the microbiome, thus avoiding AMR development to the anti-infective. This review summates the current basis of numerous anti-virulence strategies being explored for <i>N. gonorrhoeae</i>. 
546 |a EN 
690 |a <i>Neisseria gonorrhoeae</i> 
690 |a antimicrobial resistance 
690 |a sexually transmitted infections 
690 |a virulence factors 
690 |a anti-virulence therapy 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Antibiotics, Vol 10, Iss 2, p 103 (2021) 
787 0 |n https://www.mdpi.com/2079-6382/10/2/103 
787 0 |n https://doaj.org/toc/2079-6382 
856 4 1 |u https://doaj.org/article/8d814fc4c35e4fbca3dd5a66dee08080  |z Connect to this object online.